About Longdom Conferences
Longdom Conferences hosts 200+ leading international conferences and virtual events annually. It is instrumental in bringing together experts and learners from all over the globe for mutual growth and effective research-oriented discussions. As per the present market demand and growth in the field of Hematology and Blood Disorders Research, Longdom Meetings is hosting its “ International Summit on Hematology and Blood Disorders”. This is scheduled for February 27-28, 2025 in Paris, France. The field of Hematology and Blood Disorders is one of the oldest scientific subjects, which is continuously evolving and has placed many landmarks in different research and development sectors. These fields are ecological science, agronomy, healthcare, drug discovery, food technology, and many other industrial areas. The Hematology 2025 extends immense pleasure in inviting you to join us at this conference which will be focusing on the theme “Hematologic Malignancies: Emerging Therapies and Future Directions”. We aim to engage, empower, evolve, and explore knowledge among attendees from all levels of scientific research on Hematology. This Hematology and Blood Disorders conference will focus on the core knowledge and major advances in the rapidly emerging fields by attracting eminent scholars, experts, and professionals globally.
Why join LONGDOM conferences?
Understand the current state of research | Meet international colleagues and experts | Visit the exhibition of leading-edge technology | Engage with editors of the top journals in your field | Global networking and certification | Brand Launching and many more to explore
Who will be the participants?
Academic Deans and Directors | Professors and project leads | Postdocs and research scholars | Young scientists and students | CEOs/ CFOs/ Chairs/ Vice-Chairs | Marketing/ business and development teams | Experts who are keen-sighted for collaboration | Product designers and resolution workers | Business sales & services professionals | Associations and society members | Funding organizations & fundraisers
Important Scientific Sessions
Track-1: Hematologic Malignancies:
Refers to cancers that affect the blood, bone marrow, and lymph nodes. This category includes leukemia, lymphoma, and multiple myeloma. Advances in treatment, such as targeted therapies and immunotherapies, are critical in managing these malignancies. Hematologic malignancies, also known as blood cancers, are cancers that originate in the blood-forming tissues of the body, including the bone marrow and the lymphatic system. These cancers affect the production and function of blood cells, leading to abnormal proliferation and dysfunction. Hematologic malignancies are broadly categorized into three main types: leukemia, lymphoma, and myeloma.
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-2: Bone Marrow Transplantation:
A medical procedure used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. It is often used to treat certain cancers like leukemia and lymphoma, as well as other blood disorders. Recent trends focus on improving donor matching and reducing transplant-related complications. Bone marrow transplantation (BMT), also known as hematopoietic stem cell transplantation (HSCT), is a medical procedure used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Bone marrow is the soft, spongy tissue inside bones that produces blood cells, including red blood cells, white blood cells, and platelets. This procedure is commonly used to treat diseases affecting blood production, the immune system, or bone marrow itself.
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-3: Thrombosis and Hemostasis:
Thrombosis refers to the formation of a blood clot inside a blood vessel, while hemostasis is the process that prevents and stops bleeding. Research in this area is focused on understanding clot formation, improving anticoagulant therapies, and managing bleeding disorders. Thrombosis refers to the formation of a blood clot, known as a thrombus, within a blood vessel. This process can impede blood flow and lead to significant complications depending on the clot's location. Thrombosis is broadly categorized into. Thrombosis and hemostasis are critical processes in the vascular system, ensuring both the prevention of blood loss following vascular injury and the maintenance of normal blood flow. These processes are closely related, yet their dysregulation can lead to life-threatening conditions.
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-4: Sickle Cell Disease:
A genetic blood disorder characterized by the production of abnormal hemoglobin, leading to the distortion of red blood cells into a sickle shape. This condition causes severe pain, anemia, and other serious complications. Current research aims to develop gene therapies and better pain management strategies. Sickle Cell Disease (SCD) is a group of inherited blood disorders characterized by the production of abnormally shaped red blood cells. These cells, which are typically round and flexible, become rigid and shaped like a crescent or sickle. This structural abnormality impairs their ability to carry oxygen effectively and causes various complications.
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-5: Leukemia Research:
Leukemia is a type of cancer that affects the blood and bone marrow. Ongoing research is focused on understanding the genetic mutations that cause leukemia, developing targeted therapies, and improving patient outcomes through a personalized treatment approach. Leukemia, a type of cancer affecting the blood and bone marrow, has been a focus of intense research for decades. Advances in understanding its molecular mechanisms and developing innovative treatments have significantly improved survival rates, particularly for some subtypes. Here is an overview of key areas in leukemia research: Leukemia is a type of blood cancer that originates in the bone marrow, where blood cells are produced. It affects the production and function of white blood cells, which are critical for the immune system. Leukemia research focuses on understanding its causes, developing diagnostic methods, and creating effective treatments to improve patient outcomes. Here's a closer look at the major aspects of leukemia research
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-6: Anemia Management:
Anemia is a condition in which the blood lacks enough healthy red blood cells or hemoglobin. Management strategies include dietary changes, supplements, and medications. Current trends emphasize personalized treatment plans and addressing underlying causes such as chronic diseases. Anemia is a condition characterized by a decrease in the number of red blood cells (RBCs) or a reduction in hemoglobin levels, impairing the blood's capacity to carry oxygen. Effective management of anemia requires understanding its underlying causes, implementing appropriate interventions, and monitoring outcomes. Here's a detailed look at anemia management:
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-7: Gene Therapy in Hematology:
Involves the modification of a patient’s genes to treat or prevent hematologic disorders. Gene therapy is showing promise in treating conditions like sickle cell disease, hemophilia, and certain types of leukemia by correcting or replacing defective genes. Gene therapy has emerged as a revolutionary approach in hematology, addressing a range of inherited and acquired blood disorders at the molecular level. By directly altering or repairing faulty genes, gene therapy offers potential cures for diseases previously considered incurable, transforming patient care and outcomes. Gene therapy represents a revolutionary approach in the field of hematology, offering potential cures for genetic blood disorders by addressing the underlying causes at the molecular level. This cutting-edge technology focuses on modifying or replacing defective genes to restore normal function or introduce therapeutic functions into a patient's cells.
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-8: Hemophilia Treatment:
Hemophilia is a genetic disorder where blood doesn’t clot properly due to a lack of clotting factors. Treatment advancements include recombinant clotting factors, gene therapy, and non-factor therapies that reduce bleeding episodes and improve quality of life. Hemophilia is a rare genetic disorder where the blood doesn't clot properly due to the lack of sufficient clotting factors. This condition primarily affects males and can lead to excessive bleeding even from minor injuries. There are two main types: Hemophilia A, caused by a deficiency of clotting factor VIII, and Hemophilia B, caused by a deficiency of clotting factor IX. Treatment focuses on replacing the missing clotting factors and managing bleeding episodes.
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-9: Blood Clotting Disorders:
Encompasses conditions where the blood clots excessively or insufficiently, such as deep vein thrombosis (DVT) and hemophilia. Research is focused on improving diagnostic methods, treatment options, and understanding the genetic basis of these disorders. Blood clotting, or coagulation, is a vital process that helps prevent excessive bleeding when a blood vessel is injured. It involves a complex interaction between blood cells (platelets), proteins in the blood (clotting factors), and the vascular wall. However, abnormalities in this system can lead to blood clotting disorders, which are broadly classified into two categories: bleeding disorders (where the blood doesn’t clot properly) and clotting disorders (where the blood clots excessively). These conditions can have serious health consequences if not properly managed.
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-10: Platelet Disorders:
Platelets are essential for blood clotting, and disorders can lead to either excessive bleeding or clotting. Platelet disorders include thrombocytopenia (low platelet count) and thrombocythemia (high platelet count). Current research is directed towards better diagnostic tools and targeted therapies. Platelet disorders refer to a group of conditions affecting the blood platelets, also known as thrombocytes. Platelets are tiny, disc-shaped cell fragments in the blood that play a crucial role in hemostasis by forming clots to stop bleeding. Any disruption in platelet number or function can lead to bleeding or clotting issues, which are the hallmark of platelet disorders.
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-11: Lymphoma Updates:
Lymphoma is a type of blood cancer that affects the lymphatic system. Research updates include advancements in immunotherapy, targeted drug therapies, and understanding the molecular mechanisms that drive lymphoma progression. Lymphoma, a type of cancer that originates in the lymphatic system, has seen significant advancements in understanding, diagnosis, and treatment. The disease is categorized primarily into Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), with each having unique subtypes, clinical features, and therapeutic strategies. Here are the latest updates in lymphoma research and management: Advanced genomic techniques, including next-generation sequencing (NGS), are now identifying genetic mutations and molecular markers associated with various lymphoma subtypes. These tools enhance diagnostic precision and help tailor treatment strategies. The future of lymphoma treatment lies in integrating precision medicine, immunotherapy, and advanced diagnostics. As research continues to unravel the complexities of lymphoma biology, the goal remains to improve survival rates, minimize treatment toxicity, and enhance patients' quality of life.
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-12: Multiple Myeloma Advances:
Multiple myeloma is a cancer of plasma cells in the bone marrow. Recent advances include the development of novel drug therapies, improvements in stem cell transplantation, and personalized treatment approaches to extend patient survival and improve quality of life. Multiple Myeloma is a type of blood cancer that originates in plasma cells, a type of white blood cell responsible for producing antibodies. In recent years, significant advances have been made in understanding and treating this complex disease, leading to improved outcomes and extended survival for many patients. Below are some key areas of progress: Multiple Myeloma (MM) is a type of blood cancer that originates in plasma cells, a vital part of the immune system responsible for producing antibodies. In recent years, significant progress has been made in the diagnosis, treatment, and understanding of MM, offering improved outcomes and quality of life for patients. Below is an in-depth review of recent advancements.
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-13: Hematopoiesis:
The process of forming new blood cells in the body. Research in hematopoiesis focuses on understanding how blood cells are produced and regulated, with implications for treating blood disorders and improving outcomes in bone marrow transplantation. Hematopoiesis is the process by which the body produces blood cells. It occurs primarily in the bone marrow and is vital for maintaining adequate levels of red blood cells (RBCs), white blood cells (WBCs), and platelets, all of which are essential for oxygen transport, immunity, and clotting, respectively. This process is tightly regulated and involves the differentiation of hematopoietic stem cells (HSCs) into various blood cell lineages. Hematopoiesis is the process by which the body produces blood cells, encompassing the formation, differentiation, and maturation of all types of blood cells. This process is vital for maintaining a healthy blood supply and ensuring that the body has adequate resources to transport oxygen, defend against infections, and prevent bleeding.
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-14: Red Blood Cell Disorders:
Disorders affecting the red blood cells, such as anemia, thalassemia, and sickle cell disease. Current trends involve the development of gene therapies, improved diagnostic techniques, and treatments that target the underlying causes of these conditions. Red blood cell (RBC) disorders encompass a wide range of conditions affecting the structure, production, lifespan, or function of red blood cells, which are vital for transporting oxygen from the lungs to tissues and carbon dioxide from tissues back to the lungs. Understanding these disorders is crucial, as they can significantly impact health and quality of life.Red blood cells (RBCs) are crucial components of the blood responsible for transporting oxygen from the lungs to tissues and organs and carrying carbon dioxide back to the lungs for exhalation. RBC disorders affect the structure, function, or production of these cells, leading to a range of health problems. Here’s a detailed look at these disorders:
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Track-15: Coagulation Pathways:
The series of steps that lead to blood clot formation. Understanding coagulation pathways is crucial for developing new anticoagulant therapies, managing bleeding disorders, and preventing conditions like deep vein thrombosis and pulmonary embolism. The coagulation pathways are critical components of hemostasis, the process by which the body prevents excessive bleeding and maintains blood vessel integrity after injury. These pathways involve a series of tightly regulated enzymatic reactions that culminate in the formation of a fibrin clot. The coagulation cascade is traditionally divided into three interconnected pathways: the intrinsic pathway, the extrinsic pathway, and the common pathway.
Reference Conferences: Blood Disorders Summits | Anemia Management Summits | Hemophilia Treatment Events | Lymphoma Updates Conferences | Hematopoiesis Meetings | Multiple Myeloma Advances Summits | Thrombosis and Hemostasis Meetings | Platelet Disorders Conferences | Hematologic Malignancies Summits | Gene Therapy in Hematology Conferences | Red Blood Cell Disorders Events | Coagulation Pathways Summits | Hematology Meetings | Sickle Cell Disease Summits
Market Analysis:
The global hematology diagnostics market size was valued at USD 8.34 billion in 2022. It is projected to reach USD 13.50 billion by 2031, growing at a CAGR of 5.5% during the forecast period (2023–2031).Hematology studies blood diseases and their causes, symptoms, diagnosis, and prevention. The global market is propelled by the rising prevalence of blood diseases like leukemia, lymphoma, and sickle cell. Hematology diagnostics are becoming increasingly popular because of an aging population, technological advances, and rising demand for better healthcare infrastructure. Blood cell counting and characterization devices have advanced significantly since their early days in hematology testing. Automation has been applied to detect small cell populations for diagnosing rare blood conditions, resulting in less manual labor, faster results, and simpler analyzers.
